Literature DB >> 6715683

Therapeutic approach to acute pulmonary embolism.

P Duroux, G Simonneau, P Petitpretz, P Herve.   

Abstract

Many therapeutic aspects of venous thromboembolism continue to generate controversy so that the general therapeutic guidelines given below are only indicative. The first step is the diagnosis of venous thromboembolism; this is done in the vast majority of patients by visualization of blood clots using either pulmonary angiography or phlebography. The second step is to arrest the thrombotic process; the best means of doing this is to administer IV heparin. In the case of contra-indication or documented inefficacy of heparin therapy, the only therapeutic solution is to interrupt the inferior vena cava either with a clip, an umbrella or a filter. The blood clot lysis, which represents the third step, is effected by the natural fibrinolytic system. Thrombolytics , administered as a bolus of urokinase (15000 CTA U/kg), are indicated in cases of life-threatening pulmonary emboli, i.e. those with a pulmonary vascular obstruction of more than 50% and with hypotension, shock, or acute right ventricular failure. The use of thrombolytics is more questionable when they are administered to improve the quality of vascular patency. The only indication for pulmonary embolectomy is a contra-indication or inefficacy of thrombolytics . Due to the diagnostic and therapeutic difficulties, the first and most important part of the treatment of pulmonary emboli must be the broad application of prophylaxis treatment in patients with a high risk of venous thromboembolism.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6715683     DOI: 10.1007/bf00297566

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  12 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

2.  The urokinase pulmonary embolism trial. A national cooperative study.

Authors: 
Journal:  Circulation       Date:  1973-04       Impact factor: 29.690

3.  In vivo and post mortem dissolution rates of pulmonary emboli and venous thrombi in the dog.

Authors:  K M Moser; M Guisan; E E Bartimmo; A M Longo; P G Harsanyi; N Chiorazzi
Journal:  Circulation       Date:  1973-07       Impact factor: 29.690

4.  Phlebography in the prevention of recurrent pulmonary embolism--techniques and value.

Authors:  M L Thomas; M R Andress; N L Browse; E W Fletcher; J D Phillips; H P Pim; V McAllister; R H Stephenson; K Tonge
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1970-12

Review 5.  Venous thromboembolism. Three simple decisions (Part 1).

Authors:  K M Moser; P F Fedullo
Journal:  Chest       Date:  1983-01       Impact factor: 9.410

6.  Heparin-associated thrombocytopenia.

Authors:  D B Cines; P Kaywin; M Bina; A Tomaski; A D Schreiber
Journal:  N Engl J Med       Date:  1980-10-02       Impact factor: 91.245

7.  Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography.

Authors:  R Hull; J Hirsh; D L Sackett; P Powers; A G Turpie; I Walker
Journal:  N Engl J Med       Date:  1977-06-30       Impact factor: 91.245

8.  Control of heparin therapy.

Authors:  W R Pitney; J E Pettit; L Armstrong
Journal:  Br Med J       Date:  1970-10-17

9.  Mortality in patients treated for pulmonary embolism.

Authors:  J S Alpert; R Smith; J Carlson; I S Ockene; L Dexter; J E Dalen
Journal:  JAMA       Date:  1976-09-27       Impact factor: 56.272

10.  Heparin therapy in venous thromboembolism.

Authors:  J E Wilson; L J Bynum; R W Parkey
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.